In the past year, Toleranzia has conducted a series of preclinical studies to further develop its tolerance platform technology. In connection with this research, the company has discovered that certain combinations of immunomodulatory agents and protein-based tolerogens can dramatically enhance therapeutic efficacy. These discoveries form the basis for a recently filed patent application covering novel enhanced combination therapeutics for the treatment of autoimmune diseases.

“During the continuous work to develop Toleranzia´s platform technology, our drug development team made the stunning discovery that specific combinations of tolerogens and other immunomodulatory drugs acted synergistically to provide superior therapeutic efficacy. The recently filed patent application covers this concept and we strongly believe that this finding will have a major impact on our drug development programs”, comments Charlotte Fribert, CEO of Toleranzia.
 
For further information, please contact:
Charlotte Fribert - CEO, Toleranzia AB
Tel: +46 763 19 98 98
Email: charlotte.fribert@toleranzia.com
 
About Toleranzia AB (publ)
Toleranzia AB (publ) develops drugs that harness the power of the immune system for the treatment of autoimmune orphan diseases. The drugs, which target the cause of the disease, can cure or significantly alleviate the disease and not, like current treatments, merely reduce the symptoms. They have the potential to be the first long-acting or curative therapies that act specifically on the underlying cause of the autoimmune orphan disease for which they are being developed. Toleranzia's shares are listed on the Nasdaq First North Growth Market and Mangold Fondkommission AB, 08-503 015 50, CA@mangold.se, is the company's Certified Adviser.